Those strategies included, for example, the use of high-dose IL2 treatment for patients with melanoma or renal cell carcinoma [4] (this strategy has been further improved by developing more defined genetically engineered IL2 ‘muteins’ affecting specifically CD8+ cytotoxic T cells) or direct T cell co-activation using an anti-CD28 super-agonistic antibody. Here, IL2 is linked to hereditary clear cell renal cell carcinoma.